BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31992506)

  • 1. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
    Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
    Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of CNS tumors for the treatment and management of disease.
    Nie Q; Hsiao MC; Chandok H; Rowe S; Prego M; Meyers B; Omerza G; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rueter J; Reddi HV
    J Clin Neurosci; 2020 Jan; 71():311-315. PubMed ID: 31859178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay.
    Selvam P; Hsiao MC; Omerza G; Bergeron D; Rowe S; Uvalic J; Soucy M; Peracchio M; Burns S; Meyers B; Prego M; Nie Q; Ananda G; Chandok H; Kelly K; Hesse A; Reddi HV
    Mol Diagn Ther; 2020 Feb; 24(1):103-111. PubMed ID: 31754995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
    Somasegar S; Hoppenot C; Kuchta K; Sereika A; Khandekar J; Rodriguez G; Moore E; Hurteau J; Vogel TJ
    Gynecol Oncol; 2021 Nov; 163(2):220-228. PubMed ID: 34511240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
    Sa JK; Hwang JR; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim J; Kim MS; Paik ES; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee Y; Her NG; Shin YJ; Cho HJ; Kim JY; Seo YJ; Koo H; Oh JW; Lee T; Kim HS; Song SY; Bae JS; Park WY; Han HD; Ahn HJ; Sood AK; Rabadan R; Lee JK; Nam DH; Lee JW
    Genome Biol; 2019 Nov; 20(1):253. PubMed ID: 31771620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
    Tang YH; Lin CY; Lai CH
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Barroilhet L; Matulonis U
    Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genomic profiling of adrenocortical cancers in clinical practice.
    Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
    Surgery; 2021 Jan; 169(1):138-144. PubMed ID: 32709489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
    Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
    Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin (FATWO).
    Mirkovic J; Dong F; Sholl LM; Garcia E; Lindeman N; MacConaill L; Crum CP; Nucci MR; McCluggage WG; Howitt BE
    Int J Gynecol Pathol; 2019 Nov; 38(6):543-551. PubMed ID: 30134342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
    Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
    Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
    Yang JW; Choi YL
    Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage response as a therapeutic target in gynecological cancers.
    Leary A; Auguste A; Mesnage S
    Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K pathway in gynecologic malignancies.
    Salvesen HB; Werner HM; Krakstad C
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
    Wang Q; Peng H; Qi X; Wu M; Zhao X
    Signal Transduct Target Ther; 2020 Jul; 5(1):137. PubMed ID: 32728057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
    Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
    Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.